根据名称进行药物检索

Lanoxin Intravenous 与 Quin-G

Lanoxin Intravenous 与 Quin-G互相作用以及同时服用的可能性。

检测结果:

Lanoxin Intravenous <> Quin-G

现实性: 07.10.2023 评论家: 医学副博士Shkutko P.M., in

在该服务的官方手册中，已注明相关研究结果统计规定的互相作用。该互相作用或对患者健康引起不良后果，或起到良好效果。具体联合用药问题，需遵从医嘱。

用户:

谈谈你的医生之前采用这种药物在一起奎尼丁. 结合这些药物可以大大增加，血液水平和影响的地高辛。你的医生可以规定替代品，不进行互动，或者可能需要一剂量的调整或更频繁的监测通过你的医生到安全地使用这两种药物。联系您的医生，如果你遇到恶心、呕吐、腹泻、食欲丧失、视觉障碍(视力模糊；光晕约的对象；绿色或黄色视)，或异常快速或慢或不均衡的心跳，因为这些可能的迹象和症状的过度地高辛的水平。重要的是要告诉你的医生关于所有其他药物的使用，包括维生素和草药。不停止使用任何药物，没有第一个说你的医生。

医界专家:

调节剂:奎尼丁大大增加了地高辛血清水平的超过90%的病人。拟议的机制是奎尼丁抑制的P-糖蛋白介肠流出和/或肾管分泌的地高辛。血清地高辛的水平可能会增加2倍于平均水平，虽然相互作用受到高度interpatient的可变性。

管理：谨慎建议，如果地高辛必须结合使用奎尼丁. 经验性降低地高辛的给药可能是适当的，在开始奎尼丁的治疗。血清地高辛的水平和药理效果，应密切监测，并且该剂量进行相应的调整。患者应建议通知他们的医生如果他们的经验的迹象毛地黄毒性，如恶心、厌食症、视觉障碍，脉搏缓慢，或者不规则心跳。

来源

Mordel A, Halkin H, Zulty L, Almog S, Ezra D "Quinidine enhances digitalis toxicity at therapeutic serum digoxin levels." Clin Pharmacol Ther 53 (1993): 457-62
Bigger JT Jr, Leahey EB Jr "Quinidine and digoxin: an important interaction." Drugs 24 (1982): 229-39
Leahey EB Jr, Bigger JT Jr, Butler VP Jr, et al "Quinidine-digoxin interaction: time course and pharmacokinetics." Am J Cardiol 48 (1981): 1141-6
Fenster PE, Hager WD, Goodman MM "Digoxin-quinidine-spironolactone interaction." Clin Pharmacol Ther 36 (1984): 70-3
Pedersen KE, Hastrup J, Hvidt S "The effect of quinidine on digoxin kinetics in cardiac patients." Acta Med Scand 207 (1980): 291-5
Nigam SK, Burton ME, Vasko MR "Quinidine-induced digoxin toxicity after discontinuing digoxin in a patient with renal failure." Clin Pharm 3 (1984): 662-4
Marcus FI "Pharmacokinetic interactions between digoxin and other drugs." J Am Coll Cardiol 5 (1985): a82-90
Doering W "Quinidine-digoxin interaction: Pharmacokinetics, underlying mechanism and clinical implications." N Engl J Med 301 (1979): 400-4
Fenster PE, Hager WD, Perrier D, et al "Digoxin-quinidine interaction in patients with chronic renal failure." Circulation 66 (1982): 1277-80
Drescher S, Glaeser H, Murdter T, Hitzl M, Eichelbaum M, Fromm MF "P-glycoprotein-mediated intestinal and biliary digoxin transport in humans." Clin Pharmacol Ther 73 (2003): 223-31
Walker AM, Cody RJ Jr, Greenblatt DJ, Jick H "Drug toxicity in patients receiving digoxin and quinidine." Am Heart J 105 (1983): 1025-8
Das G, Barr CE, Carlson J "Reduction of digoxin effect during the digoxin-quinidine interaction." Clin Pharmacol Ther 35 (1984): 317-21
Mungall DR, Robichaux RP, Perry W, et al "Effects of quinidine on serum digoxin concentration: a prospective study." Ann Intern Med 93 (1980): 689-93
Schenck-Gustafsson K, Jogestrand T, Nordlander R, Dahlqvist R "Effect of quinidine on digoxin concentration in skeletal muscle and serum in patients with atrial fibrillation." N Engl J Med 305 (1981): 209-11
Rameis H "Quinidine-digoxin interaction: are the pharmacokinetics of both drugs altered?" Int J Clin Pharmacol Ther Toxicol 23 (1985): 145-53
Rodin SM, Johnson BF "Pharmacokinetic interactions with digoxin." Clin Pharmacokinet 15 (1988): 227-44
Angelin B, Arvidsson A, Dahlqvist R, et al "Quinidine reduces biliary clearance of digoxin in man." Eur J Clin Invest 17 (1987): 262-5
Balayssac D, Authier N, Cayre A, Coudore F "Does inhibition of P-glycoprotein lead to drug-drug interactions?" Toxicol Lett 156 (2005): 319-29
Dahlqvist R, Ejvinsson G, Schenck-Gustafsson K "Effect of quinidine on plasma concentration and renal clearance of digoxin: a clinically important drug interaction." Br J Clin Pharmacol 9 (1980): 413-8
Hirschberg R, Schaefer K, von Herrath D, et al "Digoxin-quinidine interaction in patients with renal failure." Klin Wochenschr 59 (1981): 521-2
Hager WD, Mayersohn M, Graves PE "Digoxin bioavailability during quinidine administration." Clin Pharmacol Ther 30 (1981): 594-9
Hager WD, Fenster P, Mayersohn M, et al "Digoxin-quinidine interaction: pharmacokinetic evaluation." N Engl J Med 300 (1979): 1238-41
Schenck-Gustafsson K, Dahlqvist R "Pharmacokinetics of digoxin in patients subjected to the quinidine-digoxin interaction." Br J Clin Pharmacol 11 (1981): 181-6
Bauer LA, Horn JR, Pettit H "Mixed-effect modeling for detection and evaluation of drug interactions: digoxin-quinidine and digoxin-verapamil combinations." Ther Drug Monit 18 (1996): 46-52
Hirsh PD, Weiner HJ, North RL "Further insights into digoxin-quinidine interaction: lack of correlation between serum digoxin concentration and inotropic state of the heart." Am J Cardiol 46 (1980): 863-8
Williams PJ, Lane J, Murray W, et al "Pharmacokinetics of digoxin-quinidine interaction via mixed-effect modelling." Clin Pharmacokinet 22 (1992): 66-74
Fichtl B, Doering W, Seidel H "The quinidine-digoxin interaction in patients with impaired renal function." Int J Clin Pharmacol Ther Toxicol 21 (1983): 229-33
De Lannoy IA, Koren G, Klein J, et al "Cyclosporin and quinidine inhibition of renal digoxin excretion: evidence for luminal secretion of digoxin." Am J Physiol 263 (1992): f613-22
Freitag D, Bebee R, Sunderland B "Digoxin-quinidine and digoxin-amiodarone interactions: frequency of occurrence and monitoring in australian repatriation hospitals." J Clin Pharm Ther 20 (1995): 179-83
Belz GG, Doering W, Munkes R, Matthews J "Interaction between digoxin and calcium antagonists and antiarrhythmic drugs." Clin Pharmacol Ther 33 (1983): 410-7
Holt DW, Hayler AM, Edmonds ME, Ashford RF "Clinically significant interaction between digoxin and quinidine." Br Med J 2 (1979): 1401
Pedersen KE, Christiansen BD, Klitgaard NA, Nielsen-Kudsk F "Effect of quinidine on digoxin bioavailability." Eur J Clin Pharmacol 24 (1983): 41-7
Pieroni RE, Marshall J "Fatal digoxin-quinidine interaction in an elderly woman." J Am Geriatr Soc 29 (1981): 422-5
Doering W "Effect of coadministration of verapamil and quinidine on serum digoxin concentration." Eur J Clin Pharmacol 25 (1983): 517-21